PPARA and metabolic dysfunction-associated steatohepatitis: Furthermore, in preclinical studies, multiple PPAR agonists have achieved antifibrotic results in both animal and in vitro models, such as PPARα agonists (Bezafibrate147 and GW7647148).149 PPARα agonist Gemcabene prevented steatosis, inflammation, and hepatocyte ballooning, and inhibited fibrosis progression in a high-fat/high-calorie diet-fed murine model of NASH.150 PPAR δ agonist Seladelpar (MBX-8025) reduced steatosis and liver inflammation, and improved liver fibrosis in diabetic obse mice.151